Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy, safety, pharmacodynamics, and pharmacokinetics of Selnoflast to reduce vascular inflammation in participant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Selnoflast

Snippet

Sponsor: Genentech, Inc. | Conditions: Atherosclerosis | Phase 2 | Status: RECRUITING